Four technology appraisals (TAs) have been issued by NICE, detailing evidence-based recommendations regarding whether the following drugs should be used for the specified indication:

TA459—Collagenase clostridium histolyticum for treating Dupuytren’s contracture

TA460—Adalimumab and dexamethasone for treating non-infectious uveitis

TA461—Roflumilast for treating chronic obstructive pulmonary disease*
*This guidance replaces NICE technology appraisal guidance Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244).


TA462—Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

NICE TAs assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, as well as procedures, devices, and diagnostic agents. If the TA recommends a treatment as an option, the NHS must make sure it is available within 3 months (unless otherwise specified) of the TA publication date.